Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer

BACKGROUND: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first‐in‐human (FIH) study (NCT02361723). METHODS: Chinese patients with advanced non‐mucinous high‐grade ovarian cancer (HGOC) or triple‐negative breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Yin, Yongmei, Dong, Mei, Song, Yan, Li, Wei, Huang, Xiang, Wang, Tongshan, He, Jing, Mu, Xiyan, Li, Li, Mu, Song, Zhang, Wa, Li, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826463/
https://www.ncbi.nlm.nih.gov/pubmed/33128299
http://dx.doi.org/10.1002/cam4.3575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826463/
https://www.ncbi.nlm.nih.gov/pubmed/33128299
http://dx.doi.org/10.1002/cam4.3575

Ejemplares similares